Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hélène Carinato
Observed names:
Carinato Helene,
H. Carinato,
Helene Carinato
Institutions:
Institut de Cancérologie Strasbourg,
Institut Strauss
Observed institutions:
Institut de Cancérologie Strasbourg,
Institut Strauss
OpenAlex ID:
A5043560184
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
2021
·
Hélène Carinato
, Mickaël Burgy
, et al.
·
Frontiers in Oncology
·
18
PDF
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
2020
·
Joris Mallard
, Elyse Hucteau
, et al.
·
Frontiers in Oncology
·
11
PDF
Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature
2019
·
Laura Bender
, Benoit Lhermitte
, et al.
·
World Journal of Surgical Oncology
·
9
PDF
A Pilot Study Comparing Intraoral and Transcutaneous Photobiomodulation for Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiotherapy or Chemoradiotherapy
2025
·
Jordan Eber
, Anna Schohn
, et al.
·
Journal of Clinical Medicine
·
7
PDF
Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
2018
·
Christian Borel
, Olivier Regnier-Gavier
, et al.
·
Oncotarget
·
6
PDF
Recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC): What about second-line chemotherapy combining cetuximab and platinum-doublet after EXTREME protocol?
2017
·
O. Regnier-Gavier
, P. Coliat
, et al.
·
European Journal of Cancer
·
2
Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).
2024
·
Christian Borel
, Hélène Carinato
, et al.
·
Journal of Clinical Oncology
·
1
676P ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
2022
·
J. Fayette
, E.B. Saada
, et al.
·
Annals of Oncology
·
1
PDF
930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
2020
·
H. Carinato
, M. Burgy
, et al.
·
Annals of Oncology
·
1
PB1613 Timing and clinical course of bleeding events during extended apixaban therapy for cancer-associated thrombosis: Insights from the API-CAT prospective randomised doule-blind trial
2026
·
Isabelle Mahé
, Hélène Helfer
, et al.
·
Research and Practice in Thrombosis and Haemostasis
PDF
OC 01.1 Sites and types of bleeding during extended apixaban therapy for cancer-associated thrombosis: Insights from the API-CAT prospective double-blind randomised trial
2026
·
Isabelle Mahé
, Hélène Helfer
, et al.
·
Research and Practice in Thrombosis and Haemostasis
298P Real-world antitumor activity of trastuzumab deruxtecan in rare HER2-expressing solid tumors: A monocentric case series
2026
·
P. Rivière
, L. Eberst
, et al.
·
ESMO rare cancers.
Efficacy and Safety of Weekly P-C-CTX Induction in LA-HNSCC Patients Ineligible for Upfront Cisplatin-Based Chemoradiotherapy
2026
·
Marine Oriel
, Helene Carinato
, et al.
·
Radiotherapy and Oncology
IMMUN-NEO-ORL: Evaluation of the Efficacy of Neoadjuvant Immunochemotherapy in Patients with Locally Advanced HNSCC Unresectable
2026
·
Marine Oriel
, Hélène Carinato
, et al.
·
Radiotherapy and Oncology
消化管と脳転移を伴うグレードiii髄膜腫:症例報告と文献レビュー【jst・京大機械翻訳】
2019
·
Bender Laura
, Lhermitte Benoit
, et al.
Show more works
View as search
Works count:
15
Citation count:
56
H-index:
5
I10-index:
2
Year
Topic
Type